Investors last year were spooked about the growing scrutiny by Washington and regulators on drug prices. But even as the Senate is digging in, the real problem for big pharma companies, like AstraZeneca, Pfizer, and Merck, may be that their ability to enforce higher prices has actually come to an end.
Read Full Article »
